Home › Companies › SION

Sionna Therapeutics

SION Rare disease Lead: Phase 2 3 Biotech Distilled articles ↓

Respiratory Small Molecule

Most recent annual filing: 2026-03-02

Catalyst timeline

2 trackedQuarter catalyst calendar →

Corporate updatelate 3Q 2026Corporate update, late 3Q 2026, routine
SION-451 dual combination Ph2b start2027SION-451 dual combination Ph2b start, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

SION-451

Small Molecule Target: NBD1, CFTR

Cystic Fibrosis Phase 1 oral

galicaftor

SION-2222

Small Molecule Target: TMD1, CFTR

Cystic Fibrosis Phase 1 oral AbbVie

SION-109

Small Molecule Target: ICL4, CFTR

Cystic Fibrosis Phase 1 oral Sanofi

SION-2851

Small Molecule Target: TMD1, CFTR

Cystic Fibrosis Phase 1 oral AbbVie

SION-3067

Small Molecule Target: CFTR

Cystic Fibrosis Phase 2 oral AbbVie

Discontinued (1)

SION-719 — Cystic Fibrosis · failed to achieve key activity endpoint in Phase 2a trial as add-on to standard of care

Biotech Distilled coverage (3)

2026-09-15 UPDATE: Sionna Therapeutics (SION) - The Subgroup Resurrection 🔒 Paid
2026-08-11 UPDATE: Sionna Therapeutics (SION) - The Coin Landed on Tails
2026-07-24 Sionna Therapeutics (SION) — Scientific Deep Dive for SION-719, SION-451 and the NBD1 Franchise 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.